Mutual of America Capital Management LLC Has $876,000 Holdings in PerkinElmer, Inc. (PKI)

Mutual of America Capital Management LLC lessened its stake in PerkinElmer, Inc. (NYSE:PKI) by 20.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,981 shares of the medical research company’s stock after selling 3,118 shares during the quarter. Mutual of America Capital Management LLC’s holdings in PerkinElmer were worth $876,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PKI. Balyasny Asset Management LLC purchased a new position in PerkinElmer in the 2nd quarter worth approximately $271,000. Cornerstone Capital Management Holdings LLC. boosted its holdings in PerkinElmer by 37.5% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 25,886 shares of the medical research company’s stock worth $1,763,000 after acquiring an additional 7,053 shares during the period. Cubist Systematic Strategies LLC purchased a new position in PerkinElmer in the 2nd quarter worth approximately $269,000. Nomura Holdings Inc. purchased a new position in PerkinElmer in the 2nd quarter worth approximately $567,000. Finally, Toronto Dominion Bank boosted its holdings in PerkinElmer by 26.4% in the 2nd quarter. Toronto Dominion Bank now owns 35,925 shares of the medical research company’s stock worth $2,447,000 after acquiring an additional 7,505 shares during the period. Hedge funds and other institutional investors own 90.41% of the company’s stock.

PerkinElmer, Inc. (PKI) opened at $76.39 on Friday. The company has a market capitalization of $8,420.00, a P/E ratio of 54.18, a PEG ratio of 1.74 and a beta of 0.76. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.90 and a current ratio of 1.27. PerkinElmer, Inc. has a one year low of $53.97 and a one year high of $84.49.

PerkinElmer (NYSE:PKI) last released its earnings results on Thursday, January 25th. The medical research company reported $0.97 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.94 by $0.03. The company had revenue of $641.63 million during the quarter, compared to analysts’ expectations of $619.14 million. PerkinElmer had a return on equity of 13.30% and a net margin of 12.97%. The business’s revenue was up 13.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.83 EPS. sell-side analysts anticipate that PerkinElmer, Inc. will post 3.52 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 10th. Stockholders of record on Friday, April 13th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.37%. The ex-dividend date of this dividend is Thursday, April 12th. PerkinElmer’s dividend payout ratio (DPR) is currently 19.86%.

PKI has been the subject of a number of analyst reports. Robert W. Baird restated a “buy” rating and issued a $72.00 price target on shares of PerkinElmer in a report on Friday, October 20th. Jefferies Group restated a “hold” rating and issued a $70.00 price target on shares of PerkinElmer in a report on Friday, October 20th. Morgan Stanley upped their price target on PerkinElmer from $77.00 to $78.00 and gave the stock an “overweight” rating in a report on Friday, November 3rd. ValuEngine cut PerkinElmer from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, Bank of America upgraded PerkinElmer from an “underperform” rating to a “neutral” rating and set a $78.00 price target for the company in a report on Tuesday, December 19th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company’s stock. PerkinElmer presently has a consensus rating of “Hold” and an average target price of $76.85.

In related news, Director Alexis P. Michas sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $73.18, for a total transaction of $365,900.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Andrew Okun sold 2,273 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $77.86, for a total value of $176,975.78. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,812 shares of company stock valued at $4,263,863. Company insiders own 2.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Mutual of America Capital Management LLC Has $876,000 Holdings in PerkinElmer, Inc. (PKI)” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thelincolnianonline.com/2018/02/17/mutual-of-america-capital-management-llc-has-876000-holdings-in-perkinelmer-inc-pki.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply